AMGN vs GILD vs BIIB Stock Comparison

Amgen, Gilead Sciences and Biogen Prices as of Nov 13, 2026 Peers: Industry group
AMGN Amgen Inc
$465.67 +9.3% 1M +38.6% 1Y
Market cap
$250.23B
P/E
26.6x
Revenue (TTM)
$38.90B
Div. yield
0.02%
Biotechnology Healthcare
7 wins
GILD Gilead Sciences, Inc.
$168.08 +9.5% 1M +34.2% 1Y
Market cap
$207.56B
P/E
–
Revenue (TTM)
$30.99B
Div. yield
–
Biotechnology Healthcare
2 wins
BIIB Biogen Inc.
$253.40 +8.8% 1M +53.8% 1Y
Market cap
$37.15B
P/E
106.9x
Revenue (TTM)
$10.30B
Div. yield
–
Biotechnology Healthcare
2 wins

Head to Head

11 decided of 12

Amgen leads on 7 of the 12 questions below (Amgen 7, Biogen 2, Gilead Sciences 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAMGNGILDBIIBLeader
Larger companyMarket capitalisation $250.23B $207.56B $37.15B AMGN
Cheaper on earningsLower P/E, profitable companies only 26.6x -53.7x 106.9x AMGN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 20.9x — 19.5x BIIB
Faster revenue growthRevenue growth, trailing twelve months +8.2% +6.5% +2.3% AMGN
More profitableNet margin, trailing twelve months 24.1% -12.5% 3.4% AMGN
Better return on capitalReturn on invested capital 15.6% -6.1% 1.3% AMGN
Less leveragedLower net debt / EBITDA 2.4x 43.8x 4.5x AMGN
Higher dividend yieldTrailing dividend yield 0.02% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +38.6% +34.2% +53.8% BIIB
Better 5-year returnAnnualised price return, 5 years +17.1%/yr +20.0%/yr -1.3%/yr GILD
Less volatileAnnualised volatility, 1 year 28.8% 27.5% 34.4% GILD
Higher overall scoreMean of the five percentile scores vs peers 66/100 61/100 65/100 AMGN

Percentile Scorecard

AMGNGILDBIIB

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMGNGILDBIIB
Valuation 85 #103 of 660 89 #71 of 660 91 #60 of 660
Growth 61 #245 of 619 34 #408 of 619 27 #452 of 619
Profitability 95 #32 of 595 85 #91 of 595 88 #73 of 595
Financial Health 23 #528 of 683 22 #530 of 683 32 #466 of 683
Shareholder Returns 67 #152 of 459 75 #116 of 459 90 #48 of 459
Overall 66 61 65
  • AMGN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • GILD ranked among 695 companies in Pharmaceuticals and Biotechnology
  • BIIB ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMGNGILDBIIBSPY
1 month +9.3%+9.5%+8.8% -2.0%
3 months +12.2%+21.5%+20.8% -2.8%
6 months +42.7%+29.7%+31.3% +2.0%
Year to date +42.3%+36.9%+44.0% +10.6%
1 year +38.6%+34.2%+53.8% +12.2%
3 years +72.5%+124.9%+12.5% +68.1%
3 years, per year +19.9%+31.1%+4.0% +18.9%
5 years +120.3%+149.1%-6.3% +61.4%
5 years, per year +17.1%+20.0%-1.3% +10.1%
10 years +212.4%+119.9%-20.6% +248.5%
10 years, per year +12.1%+8.2%-2.3% +13.3%

Risk

MeasureAMGNGILDBIIBSPY
Volatility, 1Y 28.8%27.5%34.4% 13.6%
Downside volatility, 1Y 28.4%24.0%33.1% 13.9%
Beta vs S&P 500, 1Y 0.490.390.38 1.00
Return / volatility, 1Y 1.341.251.57 0.90
Max drawdown, 5Y -26.7%-29.4%-64.4% -25.4%
From 52-week high -2.7%-3.7%-0.6% -3.2%
52-week high $478.48$174.48$254.87 $779.14
52-week low $313.85$118.30$164.42 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMGNGILDBIIB
P/E now vs peer median 26.8xmedian 17.0x -54.0xmedian 17.0x 107.8xmedian 17.0x
P/S now vs peer median 6.5xmedian 8.4x 6.7xmedian 8.4x 3.6xmedian 8.4x
EV/EBITDA now vs peer median 17.1xmedian 14.6x 505.3xmedian 14.6x 32.7xmedian 14.6x
P/FCF now vs peer median 26.3xmedian 19.0x 15.1xmedian 19.0x 18.1xmedian 19.0x
P/B now vs peer median 17.6xmedian 2.0x 16.0xmedian 2.0x 2.0xmedian 2.0x
PEG now vs peer median 3.86median 0.43 1.40median 0.43 -2.80median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMGNGILDBIIB
Revenue $38.90B $30.99B $10.30B
Gross profit $27.58B $24.77B $7.62B
Operating income $12.61B -$2.36B $445.10M
Net income $9.39B -$3.86B $347.50M
Free cash flow $9.58B $13.78B $2.07B
R&D $7.84B $6.33B $2.15B
EPS (diluted) $17.20 $-3.09 $2.35
Cash & equivalents $13.19B $6.44B $1.30B
Total debt $54.01B $26.23B $7.29B
Shares (diluted) 546.00M 1.25B 147.80M
Enterprise value $201.89B $182.67B $26.46B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMGNGILDBIIB
P/E 26.8x -54.0x 107.8x
P/FCF 26.3x 15.1x 18.1x
P/Operating cash flow 20.9x 14.4x 16.7x
P/S 6.5x 6.7x 3.6x
P/B 17.6x 16.0x 2.0x
P/Tangible book -48.6x -543.2x 6.8x
EV/EBITDA 17.1x 505.3x 32.7x
EV/EBIT 23.2x -96.7x 97.6x
EV/Revenue 7.5x 7.4x 4.2x
EV/FCF 30.5x 16.6x 21.0x
EV/Operating cash flow 24.3x 15.8x 19.3x
PEG (3Y EPS CAGR) 3.86 1.40 -2.80

Growth

14 metrics
MetricAMGNGILDBIIB
Revenue growth (1Y) 8.2% 6.5% 2.3%
Revenue CAGR (3Y) 13.2% 4.2% 1.0%
Gross profit growth (1Y) 15.9% 8.2% 0.6%
Gross profit CAGR (3Y) 11.8% 4.7% 0.5%
Operating income growth (1Y) 45.4% -122.5% -76.6%
Operating income CAGR (3Y) 12.5% -31.7% -34.8%
Net income growth (1Y) 34.1% -147.6% -78.4%
Net income CAGR (3Y) 7.5% -38.5% -38.1%
EPS growth (1Y) 33.1% -147.7% -78.5%
EPS CAGR (3Y) 6.9% -38.6% -38.5%
Operating cash flow growth (1Y) -8.3% 49.8% -8.4%
Operating cash flow CAGR (3Y) 4.4% 19.9% 18.2%
Free cash flow growth (1Y) -17.0% 50.4% -10.1%
Free cash flow CAGR (3Y) 0.7% 20.6% 24.9%

Profitability

14 metrics
MetricAMGNGILDBIIB
Gross margin 70.9% 79.9% 74.0%
EBITDA margin 43.9% 1.5% 12.9%
Operating margin 32.4% -7.6% 4.3%
Pretax margin 28.4% -8.2% 4.3%
Net margin 24.1% -12.5% 3.4%
FCF margin 24.6% 44.5% 20.1%
Operating cash flow margin 30.9% 46.7% 21.8%
Return on equity 72.1% -31.2% 1.8%
Return on assets 9.8% -7.7% 1.1%
Return on invested capital 15.6% -6.1% 1.3%
Return on capital employed 17.4% -6.2% 1.6%
Asset turnover 0.4x 0.6x 0.3x
Cash conversion (OCF / net income) 1.3x -3.7x 6.5x
Stock comp / revenue 1.3% 2.9% 2.9%

Financial Health

11 metrics
MetricAMGNGILDBIIB
Debt / assets 56.2% 51.0% 22.7%
Debt / equity 3.8x 2.0x 0.4x
Net debt / EBITDA 2.4x 43.8x 4.5x
Debt / FCF 5.6x 1.9x 3.5x
Liabilities / assets 85.1% 74.6% 41.0%
Equity / assets 14.9% 25.4% 59.0%
Interest coverage 4.8x -2.3x –
Current ratio 1.5x 1.4x 1.9x
Quick ratio 1.0x 1.0x 0.9x
Cash ratio 0.6x 0.5x 0.3x
Altman Z-score 2.54 3.90 3.13

Shareholder Returns

7 metrics
MetricAMGNGILDBIIB
Dividend yield 2.1% 1.9% –
Net buyback yield – 0.5% 0.1%
Shareholder yield 2.1% 2.5% 0.1%
Payout ratio (earnings) 57.1% – –
Payout ratio (FCF) 56.0% – –
Dividend growth (1Y) 6.3% – –
Dividend CAGR (3Y) 6.4% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMGNGILDBIIB
Forward P/E 20.9xFY2026 – 19.5xFY2026
EPS, next fiscal year $22.28FY2026 $-0.84FY2026 $12.97FY2026
EPS growth, next FY +2.0%FY2026 -110.3%FY2026 -15.1%FY2026
EPS growth, the year after +7.2% – +33.4%
Revenue, next fiscal year $42.01BFY2026 $29.15BFY2026 $10.09BFY2026
Revenue growth, next FY +14.3%FY2026 -1.0%FY2026 +2.1%FY2026
Revenue growth, the year after +3.1% +18.3% +11.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMGNGILDBIIB
Held by institutions 82.7% 89.6% 96.4%
Institutions holding 3,163 2,293 1,038
Change in shares held, QoQ +4.5% +5.1% +6.0%
Institutions buying 1,452 1,113 549
Institutions selling 1,219 853 294
Buyers to sellers 1.19 1.30 1.87

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AMGNGILDBIIB
AMGN 1.00 0.57 0.51
GILD 0.57 1.00 0.42
BIIB 0.51 0.42 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AMGN, GILD and BIIB?

Amgen (AMGN) is the largest by market capitalisation: Amgen (AMGN) $250.23B, Gilead Sciences (GILD) $207.56B, Biogen (BIIB) $37.15B.

Which stock is cheaper, AMGN, GILD and BIIB?

Amgen (AMGN) trades on the lowest price-to-earnings ratio (Amgen (AMGN) 26.6x, Gilead Sciences (GILD) -53.7x, Biogen (BIIB) 106.9x). On next year's consensus earnings, Biogen (BIIB) is cheapest (Amgen (AMGN) 20.9x, Biogen (BIIB) 19.5x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Amgen (AMGN) grew revenue fastest over the trailing twelve months: Amgen (AMGN) +8.2%, Gilead Sciences (GILD) +6.5%, Biogen (BIIB) +2.3%.

Which company is more profitable?

Amgen (AMGN) has the highest net margin (Amgen (AMGN) 24.1%, Gilead Sciences (GILD) -12.5%, Biogen (BIIB) 3.4%). On return on invested capital, Amgen (AMGN) leads (Amgen (AMGN) 15.6%, Gilead Sciences (GILD) -6.1%, Biogen (BIIB) 1.3%).

Which stock has performed better?

Over the past year Biogen (BIIB) returned the most: Amgen (AMGN) +38.6%, Gilead Sciences (GILD) +34.2%, Biogen (BIIB) +53.8%. Over five years, Gilead Sciences (GILD) compounded fastest (Amgen (AMGN) +17.1%/yr, Gilead Sciences (GILD) +20.0%/yr, Biogen (BIIB) -1.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Amgen (AMGN) 0.02%, Gilead Sciences (GILD) 0.00%, Biogen (BIIB) 0.00%. Gilead Sciences (GILD) and Biogen (BIIB) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Gilead Sciences (GILD) has been the steadiest (Amgen (AMGN) 28.8%, Gilead Sciences (GILD) 27.5%, Biogen (BIIB) 34.4%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AMGN, GILD and BIIB?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Amgen (AMGN) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.